'Exciting' results in prostate cancer drug trial
A new prostate cancer drug for late-stage patients with few treatment options has yielded early trial results described as “extremely exciting”.
Half the men taking the drug abiraterone experienced a substantial drop in blood levels of PSA (prostate specific antigen), the biomarker used to track prostate cancer.
